Exlinkibart

艾林奇拜单抗

Report date: 2024/02/28 10:05:35

Base Information

Drug NameExlinkibart
Drug Alias NameLVGN-6051
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsTumor necrosis factor receptor superfamily member 9 agonistsT lymphocytes stimulants
TargetsTumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsUveal melanomaSolid tumoursNeoplasm Metastasis +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLyvgen Biopharma(HK)Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLijin Biotechnology (Shanghai) Co LtdLyvgen Biopharma(HK)Ltd
Inactive CompaniesLyvgen Biopharma (Suzhou) Co Ltd
Active IndicationsUveal melanomaSolid tumoursNeoplasm Metastasis +[11] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A